Our patient's fusion consisted of breakpoints in exon 14 of EWSR1 and exon 4 of FLI1. Exon 14 of EWSR1 encodes a domain rich in glycine and arginine, and fusions at this exon have been reported with CREM in a novel myxoid mesenchymal tumor and in a malignant epithelioid neoplasm (14, 15) The breakpoint in exon 4 of FLI1 is part of a known breakpoint cluster region and is predicted to retain the ETS-type DNA-binding domain in its C-terminus (16). Here, CREM is linked to mesenchymal cell neoplasm.